I am currently looking for a good entry point here. Technology seems promising and there are several near-term catalysts. Market Cap is around $23 Million. ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally. August 24, 2020 ENDRA Life Sciences to Receive $5 Million From Early Warrant Exercises http://investors.endrainc.com/prviewer/release_only/id/4431725 "More importantly, the proceeds should extend our cash runway through key business inflection points, including establishing evaluation reference sites and initial sales in Europe, as well as the potential receipt of FDA clearance to begin commercialization in the U.S. this year." Excerpts Investor Presentation http://investors.endrainc.com/
NDRA ENDRA Life Sciences (NASDAQ: NDRA) The company sits at the intersection of two powerful trends: breakthrough liver imaging technology and next-generation treasury strategy exposure to high-momentum digital assets like HYPE. https://thestreetreports.com/endra-...y-alongside-knrx-batl-talk-dnn-vzla-in-focus/
(NASDAQ: NDRA) ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update https://www.businesswire.com/news/h...inancial-Results-and-Provides-Business-Update
NASDAQ NDRA As the global race to treat metabolic dysfunction–associated steatotic liver disease (MASLD) and expand GLP-1 therapies accelerates, a critical challenge is emerging across the pharmaceutical industry: clinical trial infrastructure is struggling to scale—especially liver imaging. With trial sizes increasing, durations extending, and global participation expanding, ENDRA Life Sciences (NASDAQ: NDRA) is positioning its TAEUS® (Thermo-Acoustic Enhanced UltraSound) technology as a potential solution to one of the largest inefficiencies in modern clinical trials. GLP-1 and MASLD Market Growth Is Outpacing Diagnostic Infrastructure The GLP-1 receptor agonist market, a key driver of metabolic disease treatment, is projected to grow from approximately $66.4 billion in 2025 to over $185 billion by 2033. At the same time: Up to 30 million Americans are expected to be on GLP-1 therapies by 2030 MASLD and MASH clinical programs are expanding globally Trials increasingly require longitudinal liver fat monitoring over 48–72 weeks These dynamics are creating unprecedented demand for scalable liver imaging solutions. MRI-Based Imaging Creates a Structural Bottleneck Currently, MRI-PDFF remains the gold standard for liver fat measurement in clinical trials. However, it introduces significant constraints: Cost per scan: $1,500–$3,000 Limited availability across global trial sites Dependence on hospital-based infrastructure Scheduling and throughput limitations As trials scale into thousands of patients across hundreds of sites, imaging becomes a major cost driver and execution bottleneck. TAEUS®: A Potential Reset of Clinical Trial Economics ENDRA’s TAEUS® platform is designed to address these limitations by leveraging: Ultrasound-based infrastructure Point-of-care deployment Rapid, repeatable liver fat measurement Internal modeling suggests that replacing MRI-based workflows with TAEUS could reduce imaging costs by approximately 90% to 96% per trial. This represents more than incremental savings—it signals a potential structural reset in how clinical trial imaging is performed and funded. Multi-Billion Dollar Efficiency Opportunity At scale, the impact becomes significant. ENDRA estimates that widespread adoption of TAEUS across GLP-1 and MASLD clinical trials could result in: Approximately $3.1 billion in imaging-related savings by 2025 Expanding to roughly $7.0 billion by 2029 These projections reflect growing trial sizes, repeated imaging requirements, and broader global deployment. The Bottom Line The expansion of MASLD and GLP-1 therapies is creating parallel demand for scalable diagnostic infrastructure. As clinical trials grow in size and complexity, imaging constraints are becoming increasingly visible. ENDRA Life Sciences (NASDAQ: NDRA) is developing TAEUS to address this gap—offering a potential pathway to: Reduce imaging costs by over 90% Unlock billions in system-wide efficiencies Enable the next phase of global metabolic disease treatment In a healthcare market defined by scale, infrastructure—not just innovation—may determine who wins.
